

**\$20M Series A to commercialize the Endocrine Activity Index (EAI),
a next-generation diagnostic to personalize breast cancer treatment**

Take precision medicine for breast cancer to a new level with EAI

Solving for an unmet need: Current breast cancer diagnostic tests do not provide the information required for **optimal treatment decisions**.

EAI fills this need with:

- ✓ A portfolio of **innovative diagnostics developed at MD Anderson Cancer Center** to optimize treatment decisions and avoid non-beneficial treatment
- ✓ A gene expression profile that measures transcriptional activity related to Estrogen Receptor (ER) and Progesterone Receptor (PR) in breast cancer tumor tissue to yield an Index Score.

Market Overview

With the addition of the EAI test, the picture becomes clearer in personalizing treatment decisions:



Current & Future Product	Market Size
Prognosis Endocrine Activity Index [™]	200,000 patients in the US/year
Chemotherapy Recurrence Score (RS)	200,000 patients in the US/year
Chemotherapy Regimen Endocrine Activity Index [™]	60,000 patients in the US/year
Endocrine Therapy No diagnostic test	310,000 patients in the US/year
ET Duration & Benefit Endocrine Activity Index [™]	200,000 patients in the US/year

Clinical Evidence & EAI Utilities

Analytical & clinical validity proven

Prognostic for 5-year disease-free survival

- ✓ **Clinical Validity**
clinically validated in multiple clinical trials with >4600 patients
- Speers, et al. 2023 (SWOG 8814)
- Metzger, et al. 2023 (CALGB 9741)
- Metzger, et al. ASCO 2024 (PALLAS)
- Penault-Llorca, et al. ASCO 2024 (PACS-01)
- ✓ **Analytical Validity**

Predictive for benefit from taxane-based dose-intense chemotherapy

- ✓ **Clinical Validity**
demonstrated that dose-intense treatment improved DFS and OS in node-positive stage II-III breast cancer patients N=613
- Metzger, et al. 2024 (CALGB 9741)
- ✓ **Analytical Validity**

Combined Recurrence Score & Endocrine Activity Index

- **Clinical Validity**
provides independent and additive information to the 21-gene Recurrence Score >750 patients
- Speers, et al. 2023 (SWOG 8814)
- Penault-Llorca, et al. ASCO 2024 (PACS-01)
- ✓ **Strong Evidence**

Predictive for benefit from endocrine therapy

- ✓ **Strong Evidence**
- Penault-Llorca, et al. ASCO 2024 (PACS-01)

Delphi Diagnostics Leadership Team

A vested team that ***knows how to execute***



Winz Casagrande
Chief Executive Officer



Andrew Levitch
Chief Financial Officer



Dr. Federico Monzon
Chief Medical Officer



J. Chuck Morrison
Chief Commercial Officer

Intellectual Property



Patent strategy provides ***exclusivity*** and ***protection*** until 2045
Exclusive worldwide license from MD Anderson to
commercialize EAI patent portfolio, including future innovations

Series A - \$20M

Use of Proceeds

Clinical Evidence Development

\$10.0M

- Multiple clinical studies across products to achieve clinical utility
- Development of Combined EAI & RS

Sales & Marketing

\$5.5M

- Invest in sales personnel and programs to grow adoption
- Marketing support to increase awareness and education
- Coverage & Reimbursement

General & Administrative

\$4.5M

- IP enhancements
- Increased operational spending on systems and laboratory expansion
- Hires to support company growth

Contact

Chuck Morrison
Chief Commercial Officer
jcmorrison@delphi-diagnostics.com